WebDec 9, 2024 · It takes about 1 year to prevent 1 nonvertebral fracture per 100 postmenopausal women. Randomized trials have shown that bisphosphonates lower … WebNov 11, 2024 · The primary efficacy benefit of denosumab compared with bisphosphonates is the larger, continuous BMD increase for at least 10 years, and growing evidence suggests denosumab may be appropriate as initial anti-osteoporosis therapy in patients at high or very high risk of fracture [73,74,75].

Time to Benefit of Statins for Primary Prevention of …

WebAug 16, 2013 · Intravenous bisphosphonates, such as zoledronic acid, present an alternative option to oral bisphosphonates, avoiding gastrointestinal adverse effects and offering regimens with less frequent dosing and thus improving adherence to therapy. WebJun 7, 2024 · For comparison, statins generally require that 200 people be treated for five years in order to prevent one heart attack. And blood pressure lowering drugs require that 70 people be treated for five years to prevent one stroke. So by those standards, one in fifteen odds of benefit are really good. 土方歳三 イケメン

(PDF) Cost and consequences of noncompliance to oral bisphosphonate …

Webbisphosphonate treatment . about 5 people get vertebral fractures even though they have bisphosphonate treatment. 20 in 100 (20%) baseline risk. On average, for every 100 people at this baseline risk who have bisphosphonate . treatment for at least 3 years, over 10 years: about 80 people will not have a vertebral fracture and would not have ... WebNov 24, 2024 · Mean age ranged from 55 (range 45-64) to 69 (range 65-75) years. All studies had a prevalence of prior cardiovascular disease (including prior angina, MI, and/or stroke) of <10% of subjects. The mean length of follow-up ranged from 2-6 years. The ARR of MACE varied from 0.4-3.9%. Only one of the eight studies reported that statins … WebApr 25, 2013 · The suggested dose of zoledronic acid is 4 mg, in a 15-minute infusion, every 3 to 4 weeks and the dose of pamidronate is 90 mg, in a 2-hour infusion, every 3 to 4 weeks, in patients with normal renal function (GRADE 1A). brilliant vukovar